WO2006026754A3 - Bicyclic heteroaryl pde4b inhibitors - Google Patents
Bicyclic heteroaryl pde4b inhibitors Download PDFInfo
- Publication number
- WO2006026754A3 WO2006026754A3 PCT/US2005/031322 US2005031322W WO2006026754A3 WO 2006026754 A3 WO2006026754 A3 WO 2006026754A3 US 2005031322 W US2005031322 W US 2005031322W WO 2006026754 A3 WO2006026754 A3 WO 2006026754A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pde4b
- bicyclic heteroaryl
- ligands
- pde4b inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05816059A EP1786813A2 (en) | 2004-09-03 | 2005-09-02 | Bicyclic heteroaryl pde4b inhibitors |
AU2005279795A AU2005279795A1 (en) | 2004-09-03 | 2005-09-02 | Bicyclic heteroaryl PDE4B inhibitors |
JP2007530399A JP2008512380A (en) | 2004-09-03 | 2005-09-02 | PDE4B inhibitor |
CA002583428A CA2583428A1 (en) | 2004-09-03 | 2005-09-02 | Bicyclic heteroaryl pde4b inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60740704P | 2004-09-03 | 2004-09-03 | |
US60/607,407 | 2004-09-03 |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2006026754A2 WO2006026754A2 (en) | 2006-03-09 |
WO2006026754A9 WO2006026754A9 (en) | 2006-04-20 |
WO2006026754A3 true WO2006026754A3 (en) | 2007-01-11 |
WO2006026754B1 WO2006026754B1 (en) | 2007-02-22 |
Family
ID=36000749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/031322 WO2006026754A2 (en) | 2004-09-03 | 2005-09-02 | Bicyclic heteroaryl pde4b inhibitors |
Country Status (7)
Country | Link |
---|---|
US (1) | US7605168B2 (en) |
EP (1) | EP1786813A2 (en) |
JP (1) | JP2008512380A (en) |
CN (1) | CN101048407A (en) |
AU (1) | AU2005279795A1 (en) |
CA (1) | CA2583428A1 (en) |
WO (1) | WO2006026754A2 (en) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6663602B2 (en) | 2000-06-16 | 2003-12-16 | Novo Nordisk A/S | Injection device |
CA2584760C (en) | 2004-10-21 | 2013-12-24 | Novo Nordisk A/S | Dial-down mechanism for wind-up pen |
RU2435769C2 (en) * | 2005-05-20 | 2011-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Pyrrolopyridines effective as proteinkinase inhibitors |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
BRPI0613153A2 (en) | 2005-06-24 | 2010-12-21 | Bayer Bioscience Nv | methods for altering plant cell wall reactivity |
DE102006012617A1 (en) * | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives |
ES2389866T3 (en) | 2006-05-18 | 2012-11-02 | Novo Nordisk A/S | Injection device with locking mode |
US8097699B2 (en) | 2006-08-30 | 2012-01-17 | Rsr Limited | Crystal structure of thyroid stimulating hormone receptor |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
AU2008276063B2 (en) | 2007-07-17 | 2013-11-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2009067597A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | 4- (or 5-) substituted catechol derivatives |
MX2010006657A (en) | 2007-12-20 | 2010-10-05 | Astrazeneca Ab | Device and method for deaggregating powder 854. |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
BRPI1015579A2 (en) | 2009-07-01 | 2019-09-24 | Astrazeneca Ab | dispenser and method for suspending dust in an air stream |
WO2011063159A1 (en) | 2009-11-18 | 2011-05-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
JP5815558B2 (en) | 2009-12-23 | 2015-11-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | Compounds and methods for kinase regulation and their indications |
AU2011214124B2 (en) | 2010-02-10 | 2014-10-30 | Astrazeneca Uk Limited | Process for providing a filled canister for an inhaler |
TWI619713B (en) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | Compounds and methods for kinase modulation, and indications therefor |
JO3131B1 (en) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | Chemical Compounds |
US8673922B2 (en) | 2010-07-15 | 2014-03-18 | Bristol-Myers Squibb Company | Azaindazole compounds |
AU2011281318B2 (en) | 2010-07-21 | 2013-09-19 | Astrazeneca Ab | Inhaler |
CN103118726B (en) | 2010-07-21 | 2015-07-22 | 阿斯利康(瑞典)有限公司 | Inhaler |
PE20141360A1 (en) | 2011-02-07 | 2014-10-13 | Plexxikon Inc | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES AND INDICATIONS FOR THEM. |
EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
RU2631487C2 (en) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Kinases modulation and indications for its use |
JP6055468B2 (en) * | 2011-07-15 | 2016-12-27 | ヴィーブ ヘルスケア ユーケー リミテッド | Azaindole compounds and methods for treating HIV |
GB201115874D0 (en) | 2011-09-14 | 2011-10-26 | Astrazeneca Ab | Inhaler |
US9533106B2 (en) | 2011-12-29 | 2017-01-03 | Novo Nordisk A/S | Torsion-spring based wind-up auto injector pen with dial-up/dial-down mechanism |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9951335B2 (en) | 2012-04-10 | 2018-04-24 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD |
WO2014026330A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
CA2883894C (en) | 2012-09-06 | 2020-08-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
NZ711896A (en) | 2012-12-21 | 2018-04-27 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
CN105121439A (en) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
PE20151997A1 (en) | 2013-03-15 | 2016-01-13 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND USES OF THEM |
MX2015015966A (en) | 2013-05-30 | 2016-04-13 | Plexxikon Inc | Compounds for kinase modulation, and indications therefor. |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
AP2017009744A0 (en) | 2014-08-06 | 2017-02-28 | Pfizer | Imidazopyridazine compounds |
EP3194392B1 (en) | 2014-09-15 | 2020-01-01 | Plexxikon, Inc. | Heterocyclic compounds and uses thereof |
CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
WO2016164641A1 (en) * | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
ES2774178T3 (en) | 2015-05-06 | 2020-07-17 | Plexxikon Inc | Synthesis of 1h-pyrrolo [2,3-B] pyridine derivatives that modulate kinases |
CN107548394B (en) | 2015-05-06 | 2020-03-24 | 普莱希科公司 | Solid forms of kinase modulating compounds |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
MY195977A (en) | 2015-09-21 | 2023-02-27 | Plexxikon Inc | Heterocyclic Compounds and uses Thereof |
EP3368539B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as ror gamma t inhibitors and uses thereof |
US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
JP2018531958A (en) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Heteroaryl-substituted benzoic acids and their use as RORγT inhibitors |
CA3007462C (en) | 2015-12-07 | 2023-10-24 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
BR112018074232A2 (en) | 2016-05-26 | 2019-03-06 | Zeno Royalties & Milestones, LLC | egfr inhibitor compounds |
TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
CA3047580A1 (en) | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
WO2018175311A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
EP3658189A1 (en) | 2017-07-25 | 2020-06-03 | Plexxikon Inc. | Formulations of a compound modulating kinases |
AU2018348241B2 (en) | 2017-10-13 | 2023-01-12 | Opna Bio SA | Solid forms of a compound for modulating kinases |
BR112020007972A2 (en) | 2017-10-27 | 2020-10-20 | Plexxikon, Inc. | compound formulations that modulate kinases |
CN112119072A (en) | 2018-03-20 | 2020-12-22 | 普莱希科公司 | Compounds and methods for IDO and TDO modulation, and indications thereof |
MX2021012278A (en) | 2019-04-09 | 2021-11-12 | Plexxikon Inc | Condensed azines for ep300 or cbp modulation and indications therefor. |
JP2023522949A (en) | 2020-04-23 | 2023-06-01 | オプナ バイオ ソシエテ アノニム | Compounds and methods for modulating CD73 and indications thereof |
AU2021327375A1 (en) | 2020-08-21 | 2023-03-16 | Opna Bio SA | Combinational drug anticancer therapies |
CN113754796B (en) * | 2021-10-18 | 2022-09-30 | 中国石油大学(华东) | Naphthalene-modified crosslinked beta-cyclodextrin gel, preparation method and application |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0667345A1 (en) * | 1994-02-14 | 1995-08-16 | Yung Shin Pharm. Ind. Co. Ltd. | 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation |
WO2001002369A2 (en) * | 1999-07-02 | 2001-01-11 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
EP1166785A1 (en) * | 2000-06-19 | 2002-01-02 | Yung Shin Pharmeutical Ind. Co., Ltd. | Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation |
WO2002062290A2 (en) * | 2000-12-20 | 2002-08-15 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
US20040106641A1 (en) * | 2000-10-27 | 2004-06-03 | Norbert Hofgen | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
WO2005016924A1 (en) * | 2003-08-13 | 2005-02-24 | Glaxo Group Limited | 7-azaindole derivatives as cox2 inhibitors |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US587707A (en) * | 1897-08-10 | Tension device for sewing-machine binders | ||
GB1573212A (en) * | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4626513A (en) * | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
EP0154734B1 (en) | 1984-03-15 | 1990-08-29 | Immunex Corporation | Immediate ligand detection assay, a test kit and its formation |
US5688655A (en) | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US5700637A (en) * | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US6054270A (en) * | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5658775A (en) * | 1988-05-17 | 1997-08-19 | Sloan-Kettering Institute For Cancer Research | Double copy retroviral vector |
US4861891A (en) * | 1988-08-31 | 1989-08-29 | Pfizer Inc. | Antidepressant N-substituted nicotinamide compounds |
WO1990002806A1 (en) * | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5527681A (en) * | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
WO1991018088A1 (en) * | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
WO1993002556A1 (en) * | 1991-07-26 | 1993-02-18 | University Of Rochester | Cancer therapy utilizing malignant cells |
US5632957A (en) * | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
JPH05236997A (en) * | 1992-02-28 | 1993-09-17 | Hitachi Ltd | Chip for catching polynucleotide |
PT705279E (en) * | 1993-05-27 | 2003-07-31 | Selectide Corp | LIBRARIES IN SOLID PHASE CODIFIED, TOPOLOGICALLY SEGREGATED |
US5840485A (en) * | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5426039A (en) * | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
US6045996A (en) * | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5965452A (en) * | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US6468742B2 (en) * | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US5807522A (en) * | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5763198A (en) * | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
US5556752A (en) * | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5830645A (en) * | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5837815A (en) | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polypeptide products |
US5959098A (en) * | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US6117681A (en) * | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
US6110456A (en) * | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
US5856174A (en) * | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5866411A (en) * | 1995-09-08 | 1999-02-02 | Pedersen; Finn Skou | Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector |
US5747276A (en) * | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
WO1997016533A1 (en) * | 1995-10-31 | 1997-05-09 | The Regents Of The University Of California | Mammalian artificial chromosomes and methods of using same |
US6022963A (en) * | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
AU3568897A (en) | 1996-06-07 | 1998-01-05 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
US5922557A (en) * | 1997-01-09 | 1999-07-13 | Merck & Co., Inc. | System for stably expressing a high-affinity camp phosphodiesterase and use thereof |
US6294330B1 (en) * | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
WO1998039471A1 (en) * | 1997-03-07 | 1998-09-11 | Tropix, Inc. | Protease inhibtor assay |
US6380218B1 (en) | 1997-04-04 | 2002-04-30 | Pfizer Inc | Nicotinamide derivatives |
CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
US6096718A (en) * | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
US6826296B2 (en) * | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
WO1999009217A1 (en) | 1997-08-15 | 1999-02-25 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
CN100337106C (en) * | 1997-09-11 | 2007-09-12 | 生物风险公司 | Method of making high density arrays |
US6178384B1 (en) * | 1997-09-29 | 2001-01-23 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for selecting a molecule based on conformational free energy |
US6465178B2 (en) * | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
MA24682A1 (en) | 1997-10-23 | 1999-07-01 | Smithkline Beecham Corp | NEW POLYMORPHIC FORMS OF CIPAMFYLLINE, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM |
ES2267873T3 (en) | 1997-10-27 | 2007-03-16 | Agouron Pharmaceuticals, Inc. | DERIVATIVES OF 4-AMINOTIAZOL, ITS PREPARATION AND USE AS INHIBITORS OF CYCLINE DEPENDENT KINASES. |
AU3463699A (en) | 1998-04-03 | 1999-10-25 | Phylos, Inc. | Addressable protein arrays |
US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6288234B1 (en) * | 1998-06-08 | 2001-09-11 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
US6113913A (en) * | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
US6277628B1 (en) * | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US20020009764A1 (en) * | 1999-10-08 | 2002-01-24 | W. Joseph Thompson | Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds |
US6277489B1 (en) * | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US6221653B1 (en) * | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
US6653151B2 (en) * | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
EP1106603A3 (en) * | 1999-12-06 | 2003-11-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
US20020165237A1 (en) * | 2000-08-11 | 2002-11-07 | Fryburg David Albert | Treatment of the insulin resistance syndrome |
AU2002215047A1 (en) * | 2000-11-21 | 2002-06-03 | Smithkline Beecham Plc | Isoquinoline derivatives useful in the treatment of cns disorders |
KR20030072614A (en) * | 2001-01-31 | 2003-09-15 | 화이자 프로덕츠 인크. | Thiazolyl-, Oxazolyl-, Pyrrolyl-, and Imidazolyl-Acid Amide Derivatives Useful as Inhibitors of PDE4 Isozymes |
GB0111186D0 (en) * | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
FR2828693B1 (en) * | 2001-08-14 | 2004-06-18 | Exonhit Therapeutics Sa | NEW MOLECULAR TARGET OF NEUROTOXICITY |
-
2005
- 2005-09-02 CA CA002583428A patent/CA2583428A1/en not_active Abandoned
- 2005-09-02 AU AU2005279795A patent/AU2005279795A1/en not_active Abandoned
- 2005-09-02 JP JP2007530399A patent/JP2008512380A/en active Pending
- 2005-09-02 CN CNA200580036980XA patent/CN101048407A/en active Pending
- 2005-09-02 WO PCT/US2005/031322 patent/WO2006026754A2/en active Application Filing
- 2005-09-02 EP EP05816059A patent/EP1786813A2/en not_active Withdrawn
- 2005-09-02 US US11/219,635 patent/US7605168B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0667345A1 (en) * | 1994-02-14 | 1995-08-16 | Yung Shin Pharm. Ind. Co. Ltd. | 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation |
WO2001002369A2 (en) * | 1999-07-02 | 2001-01-11 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
EP1166785A1 (en) * | 2000-06-19 | 2002-01-02 | Yung Shin Pharmeutical Ind. Co., Ltd. | Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation |
US20040106641A1 (en) * | 2000-10-27 | 2004-06-03 | Norbert Hofgen | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
WO2002062290A2 (en) * | 2000-12-20 | 2002-08-15 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
WO2005016924A1 (en) * | 2003-08-13 | 2005-02-24 | Glaxo Group Limited | 7-azaindole derivatives as cox2 inhibitors |
Non-Patent Citations (2)
Title |
---|
CIATTINI, P.G. ET AL.: "An efficient synthesis of 3-substituted indoles by palladium-catalyzed coupling reaction of 3-tributylstannylindoles with organic triflates and halides.", TETRAHEDRON LETTERS, vol. 35, no. 15, 1994, pages 2405 - 2408, XP002396745 * |
LEE F-Y ET AL: "Synthesis of 1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole Analogues as Novel Antiplatelet Agents", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 2001, pages 3746 - 3749, XP002239593, ISSN: 0022-2623 * |
Also Published As
Publication number | Publication date |
---|---|
JP2008512380A (en) | 2008-04-24 |
WO2006026754A9 (en) | 2006-04-20 |
CA2583428A1 (en) | 2006-03-09 |
EP1786813A2 (en) | 2007-05-23 |
AU2005279795A1 (en) | 2006-03-09 |
US20060100218A1 (en) | 2006-05-11 |
US7605168B2 (en) | 2009-10-20 |
CN101048407A (en) | 2007-10-03 |
WO2006026754B1 (en) | 2007-02-22 |
WO2006026754A2 (en) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006026754A3 (en) | Bicyclic heteroaryl pde4b inhibitors | |
WO2005062795A3 (en) | Compounds and methods for development of ret modulators | |
WO2005028624A3 (en) | Molecular scaffolds for kinase ligand development | |
WO2004078923A3 (en) | Pyk2 crystal structure and uses | |
NO20081540L (en) | thiazole | |
WO2006078287A3 (en) | Pde4b inhibitors and uses therefor | |
WO2006094292A3 (en) | Thienopyridine compounds, and methods of use thereof | |
NO20091734L (en) | Glucagon receptor antagonist compounds, preparations containing such compounds, and methods of use | |
ATE480643T1 (en) | HOMOGENEOUS DETECTION OF ANALYTES | |
WO2006071762A3 (en) | Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods | |
NL1029360A1 (en) | Substituted heteroaryl and phenylsulfamoyl compounds. | |
CY1110337T1 (en) | PREGAMPALIN PREPARATION AND RELATED UNIONS | |
ATE395336T1 (en) | QUINOLINE DERIVATIVES FOR USE AS MYCOBACTERIA INHIBITORS | |
NL1028519A1 (en) | Substituted heteroaryl and phenylsulfamoyl compounds. | |
DK1877390T3 (en) | Benzisoxazole-piperazine Compounds and Methods for Using Them | |
WO2003031606A3 (en) | Crystal structure of an aurora kinase catalytic domain, and use thereof | |
NO20045043L (en) | Pyrimidinone Compounds, Compositions and Methods | |
ATE473744T1 (en) | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | |
GT200600407A (en) | ACTIVE PPAR COMPOUNDS | |
WO2006024640A3 (en) | Triazolophthalazines | |
WO2005028678A3 (en) | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | |
DE602006010400D1 (en) | OLANZAPINE ANALOGUE AND METHOD OF USE THEREOF | |
WO2006042173A3 (en) | Modulators of hepatocyte growth factor activator | |
BRPI0517417A (en) | compound, use of a compound or an ester thereof, pharmaceutical composition, and method for screening selective prostanoid receptor ligands | |
WO2006047269A3 (en) | Pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 1/2-2/2, DRAWINGS, REPLACED BY A NEW PAGE 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 396, DESCRIPTION, REPLACED BY CORRECT PAGE 396 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2583428 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005816059 Country of ref document: EP Ref document number: 2007530399 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005279795 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005279795 Country of ref document: AU Date of ref document: 20050902 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005279795 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580036980.X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005816059 Country of ref document: EP |